Clinical trials: Pharynx Carcinoma
Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
The purpose of this study is: 1. To determine the optimal recommended phase II dose of two investigational study drugs, LBH589 and RAD001, given in combination in all solid tumors (With enrichment for EBV-Driven tumors). 2.
- Trial name
- NCT01341834
- Testing
- LBH589 and RAD001
- Where
- Singapore
- Volunteers
- 49 people
- Sponsor
- National Cancer Centre, Singapore
Throat Carcinoma
Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies
This phase II trial studies how well a web-based program called Project Prepare works in helping patients with head and neck cancer adhere to swallowing and trismus exercises and coping strategies.
- Trial name
- NCT04003051
- Testing
- Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharynx (OPX) Biomarker Trial
The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06356272
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Mayo Clinic
Nasopharyngeal Carcinoma
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
- Trial name
- NCT04813705
- Testing
- Reduced dose, Conventional dose, Chemotherapy
- Where
- 4 sites in China
- Volunteers
- 93 people
- Sponsor
- Taizhou Hospital
Nasopharyngeal Carcinoma
Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma
To see the effect if a combination of concurrent chemoradiotherapy followed by different adjuvant chemotherapy in treating patients with N2-3 nasopharyngeal carcinoma(NPC).
- Trial name
- NCT03321539
- Testing
- CCRT+GP, CCRT+PF
- Where
- 4 sites in China
- Volunteers
- 216 people
- Sponsor
- Sun Yat-sen University
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Nasopharyngeal Carcinoma
Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma
The investigators aim to evaluate the efficiency and toxicities of concurrent docetaxel and cisplatin with intensity-modulated radiotherapy in high risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT02610556
- Testing
- Cisplatin 2, Docetaxel, Cisplatin 1
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer
Circulating Biomarkers in Oropharyngeal Cancers
The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck.
- Conditions
- Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer, Tonsillar Cancer, Base of the Tongue Carcinoma
- Trial name
- CIRCOS (NCT05904327)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Örebro County
Oropharynx Cancer, Larynx Cancer
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
The aim of this study is to investigate the effect of ATRA (Vesanoid) and the effect of tailored radiotherapy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx.
- Conditions
- Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor
- Trial name
- LYSARI (NCT06706401)
- Testing
- Vesanoid, Standard radiotherapy, Tailored radiotherapy
- Where
- 8 sites in France
- Volunteers
- 460 people
- Sponsor
- Centre Leon Berard
Nasopharyngeal Carcinoma
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Trial name
- NCT06323239
- Testing
- SBRT, Low-dose Radiotherapy (LDRT), Toripalimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Radiotherapy
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of…
- Conditions
- Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
- Trial name
- NCT04448522
- Testing
- reduced dosage IMRT, conventional dosage IMRT
- Where
- 6 sites in China, Singapore
- Volunteers
- 508 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04405622
- Testing
- Toripalimab plus gemcitabine
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma Screening in Zhongshan City
The primary objective is to determine the early diagnosis rate and mortality rate of the Nasopharyngeal Carcinoma (NPC) in the study population. The secondary objective is to determine the incidence of NPC in the study population.
- Trial name
- NCT02501993
- Where
- China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Head and Neck Neoplasms, Swallowing Sparing IMRT
The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas
The aim of SWOAR TRIAL is to test sparing of Dysphagia/ Aspiration risk structures (DARS) and contra lateral submandibular gland by IMRT.
- Trial name
- SWOAR (NCT05187091)
- Testing
- Swallowing and submandibular sparing IMRT, Standard IMRT with medical CRT/RT, Cisplatine
- Where
- India
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Nasopharyngeal Carcinoma
Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- ENCORE (NCT00700440)
- Testing
- C225 (cetuximab)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
TCR-T cell therapy experienced a breakthrough for treating tumors in recent years. Phase I / II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma conducted by the Rosenberg team at the National Cancer…
- Trial name
- NCT03648697
- Testing
- EBV-TCR-T (YT-E001) cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy [IMRT]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated…
- Conditions
- Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer
- Trial name
- NCT06682442
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT06029270
- Testing
- Biospecimen Collection, Bone Scan, Carboplatin
- Where
- 95 sites in United States, Australia and 3 more
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
Organ Preservation
Functional Organ Preservation Surgery
This is a prospective randomized controlled trial comparing functional organ preservation surgery (FOPS) vs. radiotherapy or chemoradiotherapy as the first treatment modality for patients with head an neck squamous cell carcinoma…
- Trial name
- FOPS (NCT01330056)
- Testing
- FOPS, CRT
- Where
- South Korea
- Volunteers
- 264 people
- Sponsor
- Asan Medical Center
Head and Neck Squamous Cell Carcinoma
BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
Head and neck squamous cell carcinoma (include nasopharyngeal carcinoma) is one of the most common malignant tumor in China, and radiotherapy is the main treatment method.
- Trial name
- NCT05299203
- Testing
- Sapropterin dihydrochloride tablets
- Volunteers
- 18 people
- Sponsor
- West China Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.